stockrowAurinia Pharmaceuticals Inc
AUPH Healthcare Biotechnology
Aurinia Pharmaceuticals Inc’s revenue for fiscal 2025 (year ended December 2025) was $283.1 million, up 20.4% from fiscal 2024.
- Revenue
- +13.9%
- EPS
- 0.00%
- Free cash flow
- +4.41%
- Total debt
- −30.0%
Quarter to September 2026, against a year earlier
Follow AUPH
Alert me
Aurinia Pharmaceuticals Inc (AUPH) Net income
Aurinia Pharmaceuticals Inc's net income for fiscal 2025 was $287.2M, up 4,893.1% from $5.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $314.3M. Over the past ten years it has ranged from −$181.0M (fiscal 2021) to $287.2M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. Aurinia Pharmaceuticals Inc ranks 16th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $287.2M | 4,893.08% |
| FY2024 | $5.8M | — |
| FY2023 | −$78.0M | — |
| FY2022 | −$108.2M | — |
| FY2021 | −$181.0M | — |
| FY2020 | −$102.7M | — |
| FY2019 | −$88.4M | — |
| FY2018 | −$64.1M | — |
| FY2017 | −$70.8M | — |
| FY2016 | −$23.3M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $31.7M | (15.26%) |
| Jun 2026 | $37.4M | 8.90% |
| Mar 2026 | $34.4M | (83.70%) |
| Dec 2025 | $210.8M | 568.11% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc | $314.3M |
| ADMA ADMA Biologics Inc compare | $182.4M |
| VCEL Vericel Corporation compare | $33.3M |
| PVLA Palvella Therapeutics, Inc. compare | −$61.7M |
| IMNM Immunome, Inc. compare | −$254.3M |
| CLDX Celldex Therapeutics, Inc. compare | −$300.5M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| BHVN Biohaven Ltd. compare | −$542.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on AUPH
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement